Business
Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products applauds President Trump’s executive order directing the re
About this update from Avicanna Inc
[{"type":"image","alt":"Avicanna Inc.","displaySize":"","headline":null,"caption":"Avicanna Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vToBXKkzxq5ehGv_5f_3zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506","width":300,"height":300}},"lazy":false},{"type":"text","content":"Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order.","length":97,"tagName":"p"},{"type":"text","content":"Avicanna’s 2025 advances across R&D, clinical development, and medical affairs.","length":83,"tagName":"p"},{"type":"text","content":"TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products applauds President Trump’s executive order directing the reclassification of cannabis as a less dangerous substance from Schedule I to Schedule III controlled substance while also mentioning the importance of scientific research. Avicanna is also pleased to provide a scientific update on advancements across the Company’s research and development (“R&D”), clinical development, and medical affairs programs.","length":675,"tagName":"p"},{"type":"text","content":"“As a biopharmaceutical company focused on cannabinoid-based medicines, this development represents an important milestone that reinforces our long-standing commitment to standardized, evidence-based approaches to cannabinoid products,” stated Aras Azadian, CEO of Avicanna Inc. “For nearly a decade, Avicanna has actively supported and conducted research and clinical development initiatives in collaboration with leading Canadian academic and clinical institutions. We are encouraged by the recognition of the growing body of scientific evidence supporting the medical potential of cannabinoids and by the administration’s emphasis on advancing research in this field including real world evidence. We believe this regulatory direction may facilitate further clinical research, support innovation, and encourage investment into t...